Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573687 | 0.89 | PTGDR2 (0.44) | PTGS2ALDH1A1PTGDR2SMN1; SMN2MAPT | |
| SCHEMBL3568010 | 0.87 | PTGDR2 (0.47) | PTGS2ALDH1A1PTGDR2PTGS1 | |
| SCHEMBL3569716 | 0.84 | PTGDR2 (0.45) | PTGS2ALDH1A1GAAPTGDR2SMN1; SMN2 | |
| SCHEMBL2770310 | 0.78 | PTGDR2 (0.54) | PTGS2GAAPTGDR2PTGS1 | |
| SCHEMBL2770749 | 0.76 | PTGDR2 (0.42) | PTGS2PTGDR2SMN1; SMN2PTGS1 | |
| SCHEMBL3569757 | 0.75 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL3304453 | 0.73 | PTGDR2 (0.46) | ALDH1A1PTGDR2SMN1; SMN2MAPT | |
| SCHEMBL3570130 | 0.73 | PTGDR2 (0.56) | PTGS2ALDH1A1PTGDR2MAPTNPC1 | |
| SCHEMBL2771396 | 0.73 | PTGDR2 (0.50) | PTGS2ALDH1A1GAAPTGDR2MAPT | |
| SCHEMBL2768834 | 0.72 | L3MBTL1 (0.43) | PTGS2PTGDR2SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | PTGS2 426/4885ALDH1A1 831/4885GAA 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.